Dana Investment Advisors Inc. lowered its holdings in ANI Pharmaceuticals Inc (NASDAQ:ANIP) by 5.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 32,244 shares of the specialty pharmaceutical company’s stock after selling 1,730 shares during the period. Dana Investment Advisors Inc. owned approximately 0.27% of ANI Pharmaceuticals worth $1,452,000 as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in ANIP. Investment Counselors of Maryland LLC increased its position in shares of ANI Pharmaceuticals by 771.6% in the fourth quarter. Investment Counselors of Maryland LLC now owns 207,300 shares of the specialty pharmaceutical company’s stock worth $9,333,000 after acquiring an additional 183,515 shares in the last quarter. Matarin Capital Management LLC acquired a new stake in shares of ANI Pharmaceuticals in the third quarter worth $4,804,000. Phocas Financial Corp. increased its position in shares of ANI Pharmaceuticals by 131.9% in the third quarter. Phocas Financial Corp. now owns 96,805 shares of the specialty pharmaceutical company’s stock worth $5,473,000 after acquiring an additional 55,064 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of ANI Pharmaceuticals by 6.8% in the third quarter. Dimensional Fund Advisors LP now owns 511,881 shares of the specialty pharmaceutical company’s stock worth $28,941,000 after acquiring an additional 32,556 shares in the last quarter. Finally, Ontario Teachers Pension Plan Board acquired a new stake in shares of ANI Pharmaceuticals in the fourth quarter worth $1,241,000. 60.32% of the stock is owned by institutional investors.
In other news, SVP Robert W. Schrepfer sold 4,651 shares of the company’s stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $64.43, for a total value of $299,663.93. Following the completion of the transaction, the senior vice president now directly owns 53,484 shares in the company, valued at $3,445,974.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 33.10% of the stock is currently owned by corporate insiders.
Shares of ANIP stock opened at $63.49 on Friday. The firm has a market capitalization of $752.42 million, a PE ratio of 13.77 and a beta of 2.41. The company has a quick ratio of 0.68, a current ratio of 0.92 and a debt-to-equity ratio of 0.34. ANI Pharmaceuticals Inc has a twelve month low of $36.92 and a twelve month high of $72.81.
ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Wednesday, February 27th. The specialty pharmaceutical company reported $1.32 earnings per share for the quarter, beating the consensus estimate of $1.24 by $0.08. The business had revenue of $57.12 million during the quarter, compared to the consensus estimate of $53.48 million. ANI Pharmaceuticals had a net margin of 7.69% and a return on equity of 28.84%. The business’s quarterly revenue was up 20.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.08 earnings per share. On average, research analysts predict that ANI Pharmaceuticals Inc will post 5.74 EPS for the current year.
Several research analysts have recently weighed in on the stock. Raymond James set a $73.00 target price on shares of ANI Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, February 28th. BidaskClub upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, February 14th. ValuEngine upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, February 4th. Finally, Cantor Fitzgerald set a $74.00 target price on shares of ANI Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, December 28th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. ANI Pharmaceuticals has an average rating of “Buy” and a consensus target price of $71.50.
TRADEMARK VIOLATION WARNING: This piece was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2019/03/17/dana-investment-advisors-inc-sells-1730-shares-of-ani-pharmaceuticals-inc-anip.html.
ANI Pharmaceuticals Profile
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis.
See Also: Hedge Funds
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.